Treatment decisions for elderly patients with haematological malignancies: A dilemma

The Lancet Oncology

Volumn 13, Issue 8, 2012, Pages

  Peyrade, Frédéric ^a   Gastaud, Lauris ^a   Ré, Daniel ^a   Pacquelet Cheli, Sandrine ^a   Thyss, Antoine ^a  

^a Medical Oncology ^*  (France)

Author keywords

[No Author keywords available]

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTHRACYCLINE; ANTHRACYCLINE ANTIBIOTIC AGENT; ANTHRACYCLINE DERIVATIVE; AZACITIDINE; BENDAMUSTINE; CLOFARABINE; CYCLOPHOSPHAMIDE; CYTARABINE; DAUNORUBICIN; DOXORUBICIN; GEMCITABINE; GEMTUZUMAB OZOGAMICIN; IMATINIB; LENALIDOMIDE; MELPHALAN; OXALIPLATIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ACUTE GRANULOCYTIC LEUKEMIA; AGE DISTRIBUTION; ALLOGENEIC STEM CELL TRANSPLANTATION; ANEMIA; ANTINEOPLASTIC ACTIVITY; BODY HEIGHT; CANCER CONTROL; CANCER EPIDEMIOLOGY; CANCER PROGNOSIS; CANCER SURVIVAL; CANCER THERAPY; CEBPA GENE; CHRONIC MYELOID LEUKEMIA; CLINICAL DECISION MAKING; CLINICAL FEATURE; COMORBIDITY; CYTOPENIA; DOSE RESPONSE; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DISTRIBUTION; DRUG DOSE COMPARISON; DRUG DOSE REDUCTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG METABOLISM; ELDERLY CARE; EVENT FREE SURVIVAL; FEBRILE NEUTROPENIA; FRAIL ELDERLY; GASTROINTESTINAL STROMAL TUMOR; GENE; GENE MUTATION; GENETIC ASSOCIATION; GENETIC HETEROGENEITY; GERIATRIC ASSESSMENT; GLOMERULUS FILTRATION RATE; HEALTH CARE NEED; HEALTH CARE PLANNING; HEMATOLOGIC MALIGNANCY; HUMAN; IDH1 GENE; IDH2 GENE; IMMUNOSUPPRESSIVE TREATMENT; LARGE CELL LYMPHOMA; LEUKOPENIA; LIFE EXPECTANCY; LIVER CLEARANCE; LONG TERM SURVIVAL; LOW DRUG DOSE; MULTIPLE CYCLE TREATMENT; MULTIPLE MYELOMA; MYELODYSPLASTIC SYNDROME; NEUTROPENIA; NONHODGKIN LYMPHOMA; ONSET AGE; OVERALL SURVIVAL; PATIENT COMPLIANCE; PHARMACOLOGICAL PARAMETERS; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SEX RATIO; SURVIVAL RATE; THROMBOCYTOPENIA; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DECISION SUPPORT TECHNIQUES; GERIATRIC ASSESSMENT; HEALTH STATUS; HEMATOLOGIC NEOPLASMS; HUMANS; LEUKEMIA, MYELOID, ACUTE; LYMPHOMA; PATIENT SELECTION; TREATMENT OUTCOME;

EID: 84864335838     PISSN: 14702045     EISSN: 14745488     Source Type: Journal    
DOI: 10.1016/S1470-2045(12)70234-6     Document Type: Review

References (84)

1. Contents of the SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations) National Cancer Institute, (accessed May 21, 2012). http://seer.cancer.gov/csr/1975_2009_pops09/index.html.
2. Morton LM, Wang SS, Devesa SS, Hartge P, Weisenburger DD, Linet MS Lymphoma incidence patterns by WHO subtype in the United States, 1992-2001. Blood 2006, 107:265-276.
3. Groves FD, Linet MS, Travis LB, Devesa SS Cancer surveillance series: non-Hodgkin's lymphoma incidence by histologic subtype in the United States from 1978 through 1995. J Natl Cancer Inst 2000, 92:1240-1251.
4. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ Cancer statistics, 2003. CA Cancer J Clin 2003, 53:5-26.
5. Murray CJL, Lopez AD Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease Study. Lancet 1997, 349:1498-1504.
6. Hasselblom S, Ridell B, Nilsson-Ehle H, Andersson PO The impact of gender, age and patient selection on prognosis and outcome in diffuse large B-cell lymphoma-a population-based study. Leuk Lymphoma 2007, 48:736-745.
7. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:235-242.
8. Zinzani PL, Storti S, Zaccaria A, et al. Elderly aggressive-histology non-Hodgkin's lymphoma: first-line VNCOP-B regimen experience on 350 patients. Blood 1999, 94:33-38.
9. Armitage JO Is lymphoma occurring in the elderly the same disease?. Leuk Lymphoma 2008, 49:14-16.
10. Peyrade F, Jardin F, Thieblemont C, et al. Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. Lancet Oncol 2011, 12:460-468.
11. Lowenberg B, Ossenkoppele GJ, van Putten W, et al. High-dose daunorubicin in older patients with acute myeloid leukemia. N Engl J Med 2009, 361:1235-1248.
12. Mareschal S, Lanic H, Ruminy P, Bastard C, Tilly H, Jardin F The proportion of activated B-cell like subtype among de novo diffuse large B-cell lymphoma increases with age. Haematologica 2011, 96:1888-1890.
13. Park S, Lee J, Ko YH, et al. The impact of Epstein-Barr virus status on clinical outcome in diffuse large B-cell lymphoma. Blood 2007, 110:972-978.
14. Appelbaum FR, Gundacker H, Head DR, et al. Age and acute myeloid leukemia. Blood 2006, 107:3481-3485.
15. Leith CP, Kopecky KJ, Godwin J, et al. Acute myeloid leukemia in the elderly: assessment of multidrug resistance (MDR1) and cytogenetics distinguishes biologic subgroups with remarkably distinct responses to standard chemotherapy. A Southwest Oncology Group study. Blood 1997, 89:3323-3329.
16. Medeiros BC, Othus M, Fang M, Roulston D, Appelbaum FR Prognostic impact of monosomal karyotype in young adult and elderly acute myeloid leukemia: the Southwest Oncology Group (SWOG) experience. Blood 2010, 116:2224-2228.
17. Takahashi S Current findings for recurring mutations in acute myeloid leukemia. J Hematol Oncol 2011, 4:36.
18. D'Alo F, Fianchi L, Fabiani E, et al. Similarities and differences between therapy-related and elderly acute myeloid leukemia. Mediterr J Hematol Infect Dis 2011, 3:e2011052.
19. Hartmann EM, Ott G, Rosenwald A Molecular biology and genetics of lymphomas. Hematol Oncol Clin North Am 2008, 22:807-823. vii.
20. Rosenwald A, Wright G, Chan WC, et al. The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma. N Engl J Med 2002, 346:1937-1947.
21. Grimwade D, Walker H, Harrison G, et al. The predictive value of hierarchical cytogenetic classification in older adults with acute myeloid leukemia (AML): analysis of 1065 patients entered into the United Kingdom Medical Research Council AML11 trial. Blood 2001, 98:1312-1320.
22. Buchner T, Berdel WE, Haferlach C, et al. Age-related risk profile and chemotherapy dose response in acute myeloid leukemia: a study by the German Acute Myeloid Leukemia Cooperative Group. J Clin Oncol 2009, 27:61-69.
23. Klepin HD, Balducci L Acute myelogenous leukemia in older adults. Oncologist 2009, 14:222-232.
24. van der Holt B, Breems DA, Berna Beverloo H, et al. Various distinctive cytogenetic abnormalities in patients with acute myeloid leukaemia aged 60 years and older express adverse prognostic value: results from a prospective clinical trial. Br J Haematol 2007, 136:96-105.
25. Estey EH Acute myeloid leukemia: 2012 update on diagnosis, risk stratification, and management. Am J Hematol 2012, 87:89-99.
26. de Jonge HJ, de Bont ES, Valk PJ, et al. AML at older age: age-related gene expression profiles reveal a paradoxical down-regulation of p16INK4A mRNA with prognostic significance. Blood 2009, 114:2869-2877.
27. Partridge AH, Avorn J, Wang PS, Winer EP Adherence to therapy with oral antineoplastic agents. J Natl Cancer Inst 2002, 94:652-661.
28. Tsang J, Rudychev I, Pescatore SL Prescription compliance and persistency in chronic myelogenous leukemia (CML) and gastrointestinal stromal tumor (GIST) patients (pts) on imatinib (IM). Proc Am Soc Clin Oncol 2006, 24(suppl). abstr 6119.
29. Kyle RA, Rajkumar SV Multiple myeloma. N Engl J Med 2004, 351:1860-1873.
30. Dees EC, O'Reilly S, Goodman SN, et al. A prospective pharmacologic evaluation of age-related toxicity of adjuvant chemotherapy in women with breast cancer. Cancer Invest 2000, 18:521-529.
31. Lindeman RD, Tobin J, Shock NW Longitudinal studies on the rate of decline in renal function with age. J Am Geriatr Soc 1985, 33:278-285.
32. Balducci L Management of cancer in the elderly. Oncology (Williston Park) 2006, 20:135-143.
33. Thyss A, Saudes L, Otto J, et al. Renal tolerance of cisplatin in patients more than 80 years old. J Clin Oncol 1994, 12:2121-2125.
34. Doroshow JH, Synold TW, Gandara D, et al. Pharmacology of oxaliplatin in solid tumor patients with hepatic dysfunction: a preliminary report of the National Cancer Institute Organ Dysfunction Working Group. Semin Oncol 2003, 30(suppl 15):14-19.
35. Weiskopf D, Weinberger B, Grubeck-Loebenstein B The aging of the immune system. Transpl Int 2009, 22:1041-1050.
36. Balducci L ESH-SIOG International Conference on Haematological Malignancies in the Elderly. Expert Rev Hematol 2010, 3:675-677.
37. Soubeyran P, Bellera C, Goyard J, et al. Validation of the G8 screening tool in geriatric oncology: the ONCODAGE project. Proc Am Soc Clin Oncol 2011, 29(suppl). abstr 9001.
38. Nabhan C, Smith SM, Helenowski I, et al. Analysis of very elderly (>/=80 years) non-hodgkin lymphoma: impact of functional status and co-morbidities on outcome. Br J Haematol 2012, 156:196-204.
39. Röllig C, Bornhäuser M, Kramer M, et al. Pre-treatment assessment in elderly AML patients: Accuracy of prognostic predictions by the treating hematologist in 343 patients from the AML 60PLUS trial. 16th Congress of the European Hematology Association; London; June 9-12, 2011. Abstr 1018.
40. Winkelmann N, Petersen I, Kiehntopf M, Fricke HJ, Hochhaus A, Wedding U Results of comprehensive geriatric assessment effect survival in patients with malignant lymphoma. J Cancer Res Clin Oncol 2011, 137:733-738.
41. Tucci A, Ferrari S, Bottelli C, Borlenghi E, Drera M, Rossi G A comprehensive geriatric assessment is more effective than clinical judgment to identify elderly diffuse large cell lymphoma patients who benefit from aggressive therapy. Cancer 2009, 115:4547-4553.
42. Bernardi D, Milan I, Balzarotti M, Spina M, Santoro A, Tirelli U Comprehensive geriatric evaluation in elderly patients with lymphoma: feasibility of a patient-tailored treatment plan. J Clin Oncol 2003, 21:754.
43. Thieblemont C, Grossoeuvre A, Houot R, et al. Non-Hodgkin's lymphoma in very elderly patients over 80 years. A descriptive analysis of clinical presentation and outcome. Ann Oncol 2008, 19:774-779.
44. Klepin HD, Geiger AM, Tooze JA, et al. The feasibility of inpatient geriatric assessment for older adults receiving induction chemotherapy for acute myelogenous leukemia. J Am Geriatr Soc 2011, 59:1837-1846.
45. Wedding U, Rohrig B, Klippstein A, Fricke HJ, Sayer HG, Hoffken K Impairment in functional status and survival in patients with acute myeloid leukaemia. J Cancer Res Clin Oncol 2006, 132:665-671.
46. Ria R, Moschetta M, Reale A, et al. Managing myelodysplastic symptoms in elderly patients. Clin Interv Aging 2009, 4:413-423.
47. Coiffier B, Thieblemont C, Van Den Neste E, et al. Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte. Blood 2010, 116:2040-2045.
48. Bairey O, Benjamini O, Blickstein D, Elis A, Ruchlemer R Non-Hodgkin's lymphoma in patients 80 years of age or older. Ann Oncol 2006, 17:928-934.
49. Meguro A, Ozaki K, Sato K, et al. Rituximab plus 70% cyclophosphamide, doxorubicin, vincristine and prednisone for Japanese patients with diffuse large B-cell lymphoma aged 70 years and older. Leuk Lymphoma 2011, 53:43-49.
50. Musolino A, Boggiani D, Panebianco M, et al. Activity and safety of dose-adjusted infusional cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy with rituximab in very elderly patients with poor-prognostic untreated diffuse large B-cell non-Hodgkin lymphoma. Cancer 2011, 117:964-973.
51. Italiano A, Jardin F, Peyrade F, Saudes L, Tilly H, Thyss A Adapted CHOP plus rituximab in non-Hodgkin's lymphoma in patients over 80 years old. Haematologica 2005, 90:1281-1283.
52. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008, 9:105-116.
53. Osby E, Hagberg H, Kvaloy S, et al. CHOP is superior to CNOP in elderly patients with aggressive lymphoma while outcome is unaffected by filgrastim treatment: results of a Nordic Lymphoma Group randomized trial. Blood 2003, 101:3840-3848.
54. Monfardini S, Aversa SM, Zoli V, et al. Vinorelbine and prednisone in frail elderly patients with intermediate-high grade non-Hodgkin's lymphomas. Ann Oncol 2005, 16:1352-1358.
55. Visani G, Ferrara F, Alesiani F, et al. R-COMP 21 for frail elderly patients with aggressive B-cell non-Hodgkin lymphoma: a pilot study. Leuk Lymphoma 2008, 49:1081-1086.
56. Schiffer CA Postremission therapy in older adults with acute myeloid leukemia: an opportunity for new drug development. Leukemia 2002, 16:745-747.
57. Farag SS, Archer KJ, Mrozek K, et al. Pretreatment cytogenetics add to other prognostic factors predicting complete remission and long-term outcome in patients 60 years of age or older with acute myeloid leukemia: results from Cancer and Leukemia Group B 8461. Blood 2006, 108:63-73.
58. Kantarjian H, O'Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer 2006, 106:1090-1098.
59. Gardin C, Turlure P, Fagot T, et al. Postremission treatment of elderly patients with acute myeloid leukemia in first complete remission after intensive induction chemotherapy: results of the multicenter randomized Acute Leukemia French Association (ALFA) 9803 trial. Blood 2007, 109:5129-5135.
60. Derolf AR, Kristinsson SY, Andersson TM, Landgren O, Dickman PW, Bjorkholm M Improved patient survival for acute myeloid leukemia: a population-based study of 9729 patients diagnosed in Sweden between 1973 and 2005. Blood 2009, 113:3666-3672.
61. Juliusson G, Antunovic P, Derolf A, et al. Age and acute myeloid leukemia: real world data on decision to treat and outcomes from the Swedish Acute Leukemia Registry. Blood 2009, 113:4179-4187.
62. Prebet T, Boissel N, Reutenauer S, et al. Acute myeloid leukemia with translocation (8;21) or inversion (16) in elderly patients treated with conventional chemotherapy: a collaborative study of the French CBF-AML intergroup. J Clin Oncol 2009, 27:4747-4753.
63. Becker H, Marcucci G, Maharry K, et al. Favorable prognostic impact of NPM1 mutations in older patients with cytogenetically normal de novo acute myeloid leukemia and associated gene- and microRNA-expression signatures: a Cancer and Leukemia Group B study. J Clin Oncol 2010, 28:596-604.
64. Menzin J, Lang K, Earle CC, Kerney D, Mallick R The outcomes and costs of acute myeloid leukemia among the elderly. Arch Intern Med 2002, 162:1597-1603.
65. Roboz GJ Treatment of acute myeloid leukemia in older patients. Expert Rev Anticancer Ther 2007, 7:285-295.
66. Larson RA, Sievers EL, Stadtmauer EA, et al. Final report of the efficacy and safety of gemtuzumab ozogamicin (Mylotarg) in patients with CD33-positive acute myeloid leukemia in first recurrence. Cancer 2005, 104:1442-1452.
67. Castaigne S, Pantas C, Terré C, et al. Effect of gemtuzumab ozogamacin on survival in adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study. Lancet 2012, 379:1508-1516.
68. Farag SS, Maharry K, Zhang MJ, et al. Comparison of reduced-intensity hematopoietic cell transplantation with chemotherapy in patients age 60-70 years with acute myelogenous leukemia in first remission. Biol Blood Marrow Transplant 2011, 17:1796-1803.
69. Gyurkocza B, Storb R, Storer BE, et al. Nonmyeloablative allogeneic hematopoietic cell transplantation in patients with acute myeloid leukemia. J Clin Oncol 2010, 28:2859-2867.
70. Burnett AK, Milligan D, Prentice AG, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer 2007, 109:1114-1124.
71. Silverman LR, McKenzie DR, Peterson BL, et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8421, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
72. Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Azacitidine prolongs overall survival compared with conventional care regimens in elderly patients with low bone marrow blast count acute myeloid leukemia. J Clin Oncol 2010, 28:562-569.
73. Burnett AK, Russell NH, Kell J, et al. European development of clofarabine as treatment for older patients with acute myeloid leukemia considered unsuitable for intensive chemotherapy. J Clin Oncol 2010, 28:2389-2395.
74. Kantarjian HM, Erba HP, Claxton D, et al. Phase II study of clofarabine monotherapy in previously untreated older adults with acute myeloid leukemia and unfavorable prognostic factors. J Clin Oncol 2010, 28:549-555.
75. Cashen AF, Schiller GJ, O'Donnell MR, DiPersio JF Multicenter, phase II study of decitabine for the first-line treatment of older patients with acute myeloid leukemia. J Clin Oncol 2010, 28:556-561.
76. Blum W, Garzon R, Klisovic RB, et al. Clinical response and miR-29b predictive significance in older AML patients treated with a 10-day schedule of decitabine. Proc Natl Acad Sci USA 2010, 107:7473-7478.
77. Faderl S, Ravandi F, Huang X, et al. Clofarabine plus low-dose cytarabine followed by clofarabine plus low-dose cytarabine alternating with decitabine in acute myeloid leukemia frontline therapy for older patients. Cancer 2012, published online Jan 26. 10.1002/cncr.27429.
78. Italiano A, Massard C, Bahleda R, et al. Treatment outcome and survival in participants of phase I oncology trials carried out from 2003 to 2006 at Institut Gustave Roussy. Ann Oncol 2008, 19:787-792.
79. Maloney DF, Grillo-Lopez AJ, Bodkin DJ, et al. IDEC-C2B8: results of a phase I multiple-dose trial in patients with relapsed non-Hodgkin's lymphoma. J Clin Oncol 1997, 15:3266-3274.
80. Richardson PG, Schlossman RL, Weller E, et al. Immunomodulatory drug CC-5013 overcomes drug resistance and is well tolerated in patients with relapsed multiple myeloma. Blood 2002, 100:3007-3063.
81. Richardson PG, Barlogie B, Berenson J, et al. A phase 2 study of bortezomib in relapsed refractory myeloma. N Engl J Med 2003, 348:2609-2617.
82. Cohen H Drug topics red book 2008, Thomson Healthcare/Thomson PDR, Montvale, NJ. 112th edn.
83. Salles G, Seymour JF, Offner F, et al. Rituximab maintenance for 2 years in patients with high tumour burden follicular lymphoma responding to rituximab plus chemotherapy (PRIMA): a phase 3, randomised controlled trial. Lancet 2011, 377:42-51.
84. Friedberg JW Rituximab maintenance in follicular lymphoma: PRIMA. Lancet 2011, 377:4-6.